Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

Overview of attention for article published in British Journal of Dermatology, July 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 4 X users

patent: 1 patent

Readers on

mendeley: 82 Mendeley

Summary X Patents

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 16,155 followers.

RT @BrJDermatol: Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with mo…

27 Oct 2018

Reply Repost Favourite

RT @BrJDermatol: Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with mo…

27 Oct 2018

Reply Repost Favourite

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis https://t.co/qCAtCISdqP #BJD #Dermatology

27 Oct 2018

Reply Repost Favourite

@taltz @taltz #ixekinumab #Taltz https://t.co/FDPZ3yy6mR

22 May 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.